Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2010
03/11/2010US20100063013 Cathepsin cysteine protease inhibitors
03/11/2010US20100063010 Method for administering a spill resistant pharmaceutical system
03/11/2010US20100063006 Compositions and methods to reduce fat and retract skin
03/11/2010US20100062991 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof
03/11/2010US20100062972 Triazole compounds and uses related thereto
03/11/2010US20100062971 such as 2-{3-[2-(4-Methoxy-phenyl)-ethyl]-6-methyl-1H-indazol-4-yloxy} beta -D-glucopyranoside, used for for treating diabetes, Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke and cardiovascula disorders
03/11/2010US20100062968 Novel strategies for delivery of active agents using micelles and particles
03/11/2010US20100062091 Processed product of fenugreek seeds and method for producing the same
03/11/2010US20100062087 Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing
03/11/2010US20100062080 Elemental indium and indium compounds suitable for human, mammal, fowl and reptilian nutrition
03/11/2010US20100062065 Pharmaceutical composition containing naphthoquinone-based compound for intestine delivery system
03/11/2010US20100062005 Methods and Compounds for Lymphoma Cell Detection and Isolation
03/11/2010US20100061997 Transgenic Non-Human Animals Expressing A Truncated Activin Type II Receptor
03/11/2010US20100061993 Antibodies
03/11/2010US20100061964 Method for preparing pancreatic beta cells starting from beta cell progenitors and beta cells thereby obtained
03/11/2010US20100061959 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning
03/11/2010US20100061939 Chewing Gum
03/11/2010DE102008051572A1 Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder Preparation of phosphate binders and phosphate binders thus prepared
03/11/2010CA2738231A1 Novel choline cocrystal of epalrestat
03/11/2010CA2736304A1 Pyrazolopyrimidines and their use for the treatment of cns disorders
03/11/2010CA2735913A1 A method for combating adverse effects arising from antipsychotic treatment
03/11/2010CA2735842A1 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
03/11/2010CA2735828A1 Substituted-(naphthalen-1-yl)-1h-imidazoles and their use for modulating uric acid levels
03/11/2010CA2735826A1 Reducing cholesterol levels with combined use of quercetin and statin
03/11/2010CA2735794A1 Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
03/10/2010EP2161282A1 Peptide analogues of PACAP
03/10/2010EP2161265A2 Compounds having selective inhibiting effect at GSK3
03/10/2010EP2160470A2 Chimeric pufa polyketide synthase systems and uses thereof
03/10/2010EP2160387A2 Heteroarylamide pyrimidone compounds
03/10/2010EP2029558B1 Compounds and methods for modulating fxr
03/10/2010EP1715865B1 Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid
03/10/2010EP1377293B1 Aryl and biaryl piperidines used as mch antagonists
03/10/2010CN101664388A transnasal transport/immunisation with highly adaptable carriers
03/10/2010CN100593543C Hemin production process
03/09/2010US7674938 Selective beta 3-adrenoceptor stimulants; obesity, diabetes mellitus, hyperlipidemia, pollakiuria, urinary incontinence, intestinal hypermotility; e.g. 4'-{2-[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methyl ethylamino]ethoxy}-2,3',5'-trimethylbiphenyl-4-carboxylic acid
03/09/2010US7674830 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
03/09/2010US7674803 Thiazolypiperidine derivatives as MTP inhibitors
03/09/2010US7674795 Fluorene derivatives, composition containing said derivatives and the use thereof
03/09/2010US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants
03/09/2010US7674773 Glycosylated derivative of hypolipemic agents; side effect reduction; therapy for insulin resistance; hyperlipidemia agent; impaired lipid metabolism; lowering cholesterol levels
03/09/2010US7674490 Food and vitamin preparations containing the natural isomer of reduced folates
03/09/2010US7674463 Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist
03/09/2010US7674455 treating a mammal having amyotrophic lateral sclerosis by transducing a motor neuron of the mammal with an insulin-like growth factor I (IGF-1) gene or a glial cell line-derived neurotrophic factor (GDNF) gene; neurodegenerative disorders
03/09/2010CA2482346C Substituted phenylacetamides and their use as glucokinase activators
03/09/2010CA2379282C Amido spiropiperidines promote the release of growth hormone
03/09/2010CA2336702C Sulfonylaminocarboxylic acid n-arylamides as guanylate cyclase activators
03/04/2010WO2010025436A2 Nitrogen and sulfur-containing heterocycle derivatives
03/04/2010WO2010025410A2 Screening method for identifying patients at risk of adverse hepatologic events
03/04/2010WO2010025370A2 Preparation of ranolazine
03/04/2010WO2010025251A2 Materials and methods for modulating appetite, weight gain and adhd using varenicline
03/04/2010WO2010024405A1 Ifn type-1 production inhibitor and method for searching for same
03/04/2010WO2010024396A1 NOVEL EPIGALLOCATECHIN GALLATE TRIMER, AND α-GLUCOSIDASE INHIBITOR COMPRISING EPIGALLOCATECHIN GALLATE POLYMER
03/04/2010WO2010024393A1 Novel epigallocatechin gallate tetramer, and vascular endothelial function improver comprising same
03/04/2010WO2010024258A1 Ring-fused azole derivative having pi3k-inhibiting activity
03/04/2010WO2010024110A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative
03/04/2010WO2010023931A1 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same
03/04/2010WO2010023594A1 Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
03/04/2010WO2010023572A1 Herbal extract as sensitivity enhancer toward insulin and antidiabetes
03/04/2010WO2010023161A1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
03/04/2010WO2010022850A1 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
03/04/2010WO2010022497A1 Method of treating dysglycemia and glucose excursions
03/04/2010WO2010022412A1 Octahydroquinolizines for antidiabetic treatment
03/04/2010WO2009156860A3 4-(pyridin-4-yl)-1h-(1, 3, 5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
03/04/2010WO2009138437A4 Salicylate conjugates useful for treating metabolic disorders
03/04/2010WO2009124950A3 4-methyl-4,5-dihydro-1h-pyrazole-3-carboxamide useful as a cannabinoid cb1 neutral antagonist
03/04/2010US20100056613 Spiroquinone compound and pharmaceutical composition
03/04/2010US20100056610 HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS
03/04/2010US20100056600 11beta-hsd1 active compounds
03/04/2010US20100056597 Indoledione derivative
03/04/2010US20100056583 Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation
03/04/2010US20100056580 Novel crystalline salt form of an antidiabetic compound
03/04/2010US20100056560 Use for treating obesity and diabetes
03/04/2010US20100056553 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
03/04/2010US20100056550 Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
03/04/2010US20100056548 Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
03/04/2010US20100056546 Sulfonylurea inhibitors of atp-sensitive potassium channels
03/04/2010US20100056530 Glucokinase activators
03/04/2010US20100056518 Cycloalkylamine substituted isoquinolone derivatives
03/04/2010US20100056506 Substituted 2-amino-fused heterocyclic compounds
03/04/2010US20100056496 Muscarinic receptor antagonists
03/04/2010US20100056460 Combination of organic compounds
03/04/2010US20100056459 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
03/04/2010US20100056451 Stabilized Pharmaceutical Peptide Compositions
03/04/2010US20100056450 Method For Reducing Postprandial Blood Glucose Levels With A Whey Protein/Fiber Composition
03/04/2010US20100056449 Whey Protein Pre-Load
03/04/2010US20100056442 Use of gpr101 receptor in methods to identify modulators of hypothalamic proopiomelanocortin (pomc)-derived biologically active peptide secretion useful in the treatment of pomc-derived biologically
03/04/2010US20100056436 Pharmaceutical Compositions Including Low Dosages of Desmopressin
03/04/2010US20100056435 Depsipeptides and Their Therapeutic Use
03/04/2010US20100056434 Depsipeptides and Their Therapeutic Use
03/04/2010US20100055215 Process to lose weight, drain unwanted body fats and other toxins
03/04/2010US20100055204 Use of hydrochloric acid in the manufacture of medicament for treating disease caused by fouling of transport tract
03/04/2010US20100055197 Long-term enteral feed for maintenance
03/04/2010US20100055176 Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia
03/04/2010US20100055159 Percutaneous preparations
03/04/2010CA2735582A1 Screening method for identifying patients at risk of adverse hepatologic events
03/04/2010CA2735286A1 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
03/04/2010CA2735204A1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
03/04/2010CA2734981A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative
03/04/2010CA2733795A1 Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
03/03/2010EP2159221A1 Glucagon receptor antagonists, preparation and therapeutic uses
1 ... 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 ... 1298